Soo Aleman

Soo Aleman is an Adjunct Professor at the Department of Medicine, Huddinge, Karolinska Institutet, where she leads the research group 'Clinical and translational studies on viral hepatitis.' Her work focuses on viral hepatitis B/C/D, COVID-19 immunology, and liver cancer epidemiology. She serves as Research and Education Director for Theme Acute and Reparative Medicine at Karolinska University Hospital.

Her research spans observational cohorts, clinical trials, and translational studies, with emphasis on:

• Viral pathogenesis and host immune responses
• Long-term outcomes of antiviral therapies
• Pandemic-related impacts on immunocompromised populations
• Novel therapeutics (e.g., bulevirtide for hepatitis D)

Her publications (2022-2025) predominantly explore:

• SARS-CoV-2 immunity in vulnerable cohorts
• Real-world efficacy of hepatitis therapies
• Biomarkers for long COVID and liver disease progression
• Public health strategies for viral hepatitis elimination

She supervises 6 PhD students and collaborates internationally with institutions including Harvard University, Milan University Hospital, and EU consortia. Major grants include:

• Swedish Research Council: Long COVID mechanisms (2021-2025)
• Swedish Heart-Lung Foundation: Immunological correlates of long COVID (2021)
• Swedish Cancer Society: Hepatitis-related liver cancer studies (2017-2018)

Her lab includes senior researchers, postdoctoral fellows, and clinical staff specializing in virology, immunology, and patient-centered outcomes.